Abstract

 The Objective of this Literature Review is to find any published scientific evidence to correlate the use of both Thermotherapy [Hyperthermia][Heat Therapy] and Vibroacoustic therapy [Vibration + Sound] to prevent and possibly reverse chronic neurological conditions like Dementia and Alzheimer’s Disease.

Keywords: Thermotherapy; Vibroacoustic Therapy; Alzheimer’s Diseases

References

1. Access Economics (Firm), and Parkinson’s Australia. Living with Parkinson’s Disease: Challenges and Positive Steps for the Future. Scullin: Access Economics (2007).
2. H Katsuno., et al. “Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications”. International Journal of Hyperthermia 25 (2009): 647-654.
3. Ahlskog JE. “Does vigorous exercise have a neuroprotective effect in Parkinson disease?” Neurology 77 (2011): 288-294.
4. Akerman AP., et al. “Heat therapy vs. supervised exercise therapy for peripheral arterial disease: a 12-week randomized, controlled trial”. American Journal of Physiology-Heart and Circulatory Physiology 316 (2019): H1495-H1506.
5. Akinyemi RO., et al. “Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer’s disease and vascular dementia”. Current Alzheimer Research 10 (2013): 642-653.
6. Amorim FT., et al. “Insights into the role of heat shock proteins 72 to whole-body heat acclimation in humans”. Temperature 2 (2015): 499-505.
7. Asahina M., et al. “Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology”. Journal of Neurology, Neurosurgery, and Psychiatry 84 (2013): 674.
8. Auluck PK., et al. “Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease”. Science 295 (2002): 865-868.
9. Averna M., et al. “Functional role of HSP90 complexes with endothelial nitric-oxide synthase (eNOS) and calpain on nitric oxide generation in endothelial cells”. Journal of Biological Chemistry 283 (2008): 29069-29076.
10. Bennett AF. “Thermal dependence of muscle function”. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 247 (1984): R217-R229.
11. Berardelli, A., et al. “Pathophysiology of bradykinesia in Parkinson’s disease”. Brain 124 (2001): 2131-2146.
12. Bergh U and Ekblom B. “Influence of muscle temperature on maximal muscle strength and power output in human skeletal muscles”. Acta Physiologica Scandinavica 107 (1979): 33-37.
13. Bharadwaj, P., et al. “The link between type 2 diabetes and neurodegeneration: roles for Amyloid-beta, Amylin, and Tau proteins”. Journal of Alzheimer's Disease 59 (2017): 421-432.
14. Braak, H., et al. “Staging of brain pathology related to sporadic Parkinson’s disease”. Neurobiology Aging 24 (2003): 197-211.
15. Brazaitis M., et al. “Heat acclimation does not reduce the impact of hyperthermia on central fatigue”. European Journal of Applied Physiology 109 (2010): 771-778.
16. Breen D P., et al. “Gut-brain axis and the spread of alpha-synuclein pathology: vagal highway or dead end?” Movement Disorder 34 (2019): 307-316.
17. Brunt VE., et al. “Passive heat therapy improves cutaneous microvascular function in sedentary humans via improved nitric oxide-dependent dilation”. Journal of Applied Physiology 121 (2016a): 716-723.
18. Brunt VE., et al. “Passive heat therapy improves endothelial function, arterial stiffness and blood pressure in sedentary humans”. Journal of Physiology 594 (2016b): 5329-5342.
19. Brunt VE., et al. “Serum from young, sedentary adults who underwent passive heat therapy improves endothelial cell angiogenesis via improved nitric oxide bioavailability”. Temperature 6 (2019): 169-178.
20. Brunt VE., et al. “Passive heat therapy protects against endothelial cell hypoxia-reoxygenation via effects of elevations in temperature and circulating factors”. Journal of Physiology 596 (2018): 4831-4845.
21. Buchman A and Bennett DA. “Loss of motor function in preclinical Alzheimer’s disease”. Expert Review on Neurotherapy 11 (2011): 665-676.
22. Burns J M., et al. “Reduced lean mass in early Alzheimer disease and its association with brain atrophy”. Archives of Neurology 67 (2010): 428-433.
23. Cano-de-la-Cuerda R., et al. “Is there muscular weakness in Parkinson’s disease?” American Journal of Physical Medicine and Rehabilitation 89 (2010): 70-76.
24. Carman A., et al. “Chaperone-dependent Neurodegeneration: a molecular perspective on therapeutic intervention”. Journal of Alzheimers Disease and Parkinsonism (2013): 007.
25. Castro D M., et al. “The economic cost of Alzheimer’s disease: family or public health burden?” Dementia and Neuropsychologia 4 (2010): 262-267.
26. Ciechanover, A., et al. “Protein quality control by molecular chaperones in Neurodegeneration”. Frontiers in Neuroscience 11 (2017): 185.
27. Connolly EM., et al. “Pharmacological induction of HSP27 attenuates intimal hyperplasia in vivo”. European Journal of Vascular and Endovascular Surgery 25 (2003): 40-47.
28. Danzer KM., et al. “Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity”. FASEB Journal 25 (2011): 326-336.
29. Davies CT and Young K. “Effect of temperature on the contractile properties and muscle power of triceps surae in humans”. Journal of Applied Physiology 55 (1983): 191-195.
30. de la Torre JC. “Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics”. Lancet Neurology 3 (2004): 184-190.
31. De Marinis M., et al. “Alterations of thermoregulation in Parkinson’s disease”. Functional Neurology 6 (1991): 279-283.
32. Dodd SL., et al. “Hsp27 inhibits IKKbeta-induced NF-kappaB activity and skeletal muscle atrophy”. FASEB Journal 23 (2009): 3415-3423.
33. Dorsey ER., et al. “Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016”. Lancet Neurology 17 (2018): 939-953.
34. Ely BR., et al. “Heat therapy improves glucose tolerance and adipose tissue insulin signaling in polycystic ovary syndrome”. American Journal of Physiology-Endocrinology and Metabolism 317 (2019): E172-E182.
35. Evans CG., et al. “Heat shock proteins 70 and 90 inhibit early stages of amyloid beta- (1-42) aggregation in vitro”. Journal of Biological Chemistry 281 (2006): 33182-33191.
36. Evens A and Clark C. “Does assisted cycling improve function in those with Parkinson’s disease?” Physical Therapy Reviews 22 (2017): 243-253.
37. Faulkner SH., et al. “The effect of passive heating on heat shock protein 70 and interleukin-6: a possible treatment tool for metabolic diseases?” Temperature 4 (2017): 292-304.
38. Findley LJ. “The economic impact of Parkinson’s disease”. Parkinsonism and Related Disorders 13 (2007): S8-S12.
39. Fontaine SN., et al. “Neurodegeneration and the heat shock protein 70 machinery: implications for therapeutic development”. Current Topics in Medicinal Chemistry 16 (2016): 2741-2752.
40. Frazer AK., et al. “Determining the potential sites of neural adaptation to cross-education: implications for the cross-education of muscle strength”. European Journal of Applied Physiology 118 (2018): 1751-1772.
41. Galton CJ., et al. “Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases”. Brain 123 (2000): 484-498.
42. Gao X., et al. “Human Hsp70 disaggregase reverses parkinson’s-linked alpha-synuclein Amyloid fibrils”. Molecular Cell 59 (2015): 781-793.
43. Gibson OR., et al. “Extracellular Hsp72 concentration relates to a minimum endogenous criteria during acute exercise-heat exposure”. Cell Stress Chaperones 19 (2014): 389-400.
44. Gibson OR., et al. “Isothermic and fixed-intensity heat acclimation methods elicit equal increases in Hsp72 mRNA”. Scandinavian Journal of Medicine Science 25 (2015a): 259-268.

Citation

Citation: George Grant and Jay P Vanden Heuvel. “Thermotherapy and Vibroacoustic Therapy in Preventing and Possibly Reversing Dementia and Alzheimer’s". Acta Scientific Neurology 3.8 (2020): 24-36.

Copyright

Copyright: © 2020 George Grant and Jay P Vanden Heuvel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.